Precision biosciences inc stock.

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in …Dec 1, 2023 · Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More. Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...7.24%. $256.56M. AEterna Zentaris Inc. 8.87%. $10.73M. RNA | Complete Avidity Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Feb 24, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including ...This Stock Purchase Agreement (this “Agreement”) is entered into as of June 14, 2022 (the “Execution Date”), by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, with its principal business office located at 302 E Pettigrew St - Dibrell Whse Suite A-100, Durham, North Carolina ...

On average, Wall Street analysts predict that Precision Biosciences's share price could reach $2.50 by Sep 19, 2024. The average Precision Biosciences stock ...Advertisement ICYMI: The best interviews, highlights, and moments from Yahoo Finance Invest Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. …

DTIL stock, the ticker symbol for Precision BioSciences Inc, had a significant increase in its price on November 7, 2023. According to data from CNN Money, the 12-month price forecasts provided by four analysts for DTIL stock have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.Precision BioSciences, Inc. : DTIL Stock Price | US74019P1084 | MarketScreener. Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 …DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …Dec 1, 2023 · 3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price. Precision BioSciences, Inc. Common Stock (DTIL) Stock Price, Quote, News & History | Nasdaq MY QUOTES: DTIL Edit my quotes Precision BioSciences, Inc. Common Stock (DTIL)...

Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including ...

DTIL | Complete Precision Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Precision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the companyJun 22, 2023 · Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. Aug 8, 2023 · ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. Learn more about ARCUS Genome Editing › Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences (DTIL Quick Quote DTIL - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 27.5% over the past four weeks, the stock looks ...Jun 21, 2022 · Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ... Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at ...

The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Nov 7, 2023 · DTIL stock, the ticker symbol for Precision BioSciences Inc, had a significant increase in its price on November 7, 2023. According to data from CNN Money, the 12-month price forecasts provided by four analysts for DTIL stock have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00. Dec 21, 2021 · DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ... Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …WebApr 28, 2023 · On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum ...

Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Precision BioSciences' stock was trading at $1.19 at the start of the year. Since then, DTIL stock has decreased by 69.3% and is now trading at $0.3650. View the …November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ... Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s lead CD19 …WebPrecision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the companyPrecision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.SAN DIEGO, Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the …Precision BioSciences Stock Forecast. All Analysts Top Analysts DTIL's stock price has decreased by -71.36% in the past year and price targets may not have had time to catch up. Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for DTIL stock stock is $3.00, which predicts an increase of …

Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …

Common stock . This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share. Prior to this offering, there has been no public market for our common stock.

On average, Wall Street analysts predict that Precision Biosciences's share price could reach $2.50 by Sep 19, 2024. The average Precision Biosciences stock ...For more information about our programs, see our current corporate deck.WebHC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.22 thg 6, 2022 ... Latham & Watkins Represents Precision BioSciences in US$50 Million Offering of Common Stock ... Precision BioSciences, Inc. (Nasdaq: DTIL), a ...Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO …WebOn Friday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock fall -5.64% to $0.40. On the same session, the stock had its day’s lowest price of $0.3853, but rose to a high of $0.44. Over the last five days, the stock has gained 4.63%. Precision Biosciences Inc shares have fallen nearly -66.40% since the year began.Nov 7, 2023 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ... In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ...

BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT. HC Wainwright Lowers Price Target on Precision BioSciences to $17 from $20, Keeps Buy Rating. Nov. 10. MT. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …2.40%. $1.21B. IDYA | Complete IDEAYA Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... Instagram:https://instagram. forex trading demo account loginai powered equity etfnew nvidia cardssblgx Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an …WebGet a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more. clean energy stock priceeasiest fha lenders Nov 7, 2023 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ... See the latest Precision BioSciences Inc stock price (DTIL:XNAS), related news, valuation, dividends and more to help you make your investing decisions. goog stock dividend Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).. The company announced the promotion of Neil …In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ...DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim ...